Skip to main content Skip to search Skip to main navigation

Swissmedic: Invalid Certification of the Notified Body ECM

On 9 January 2024, the Swiss Medicines Agency Swissmedic informed about critical deficits in the system of medical device regulation. 

To ensure safety and efficiency, medical devices and the quality management system of medical device manufacturers are inspected and continuously monitored by notified bodies. The German notified body ECM (ECM-Zertifizierungsgesellschaft für Medizinprodukte in

Europa GmbH, Aachen) used to be such a notified body until its designation expired on 25 May 2020 and has not been renewed by the corresponding German authority. Since then, ECM-certified products have no longer been monitored in accordance with the requirements of the Therapeutic Products Act.

Last year, Swissmedic discovered that ECM certified medical devices of foreign manufacturers were still being sold in Switzerland. In response, the Swiss authority informed the approximately 980 registered Swiss authorised representatives of foreign manufacturers about the problem in June 2023 and asked them to review their mandates.

During the period from July to October 2023, the Swiss authority then carried out extensive research for a sample check. This revealed that 7 of the 15 specifically selected authorised representatives had products with an ECM certificate in their portfolio.

Swissmedic has ordered the authorised representatives concerned to take corrective action to ensure that the products distributed in Switzerland comply with the regulatory requirements.


Source:

Swissmedic:  Announcements on market control issues

Meet the GMP Compliance Adviser

The GMP Compliance Adviser is the world's largest knowledge portal for quality management in the pharma business. 

The demo access is non-binding and ends automatically.

Test it now for free

You may also be interested in the following articles:

EMA: Revision of Annex 6 - Manufacture of Medicinal Gases

EMA: Revision of Annex 6 - Manufacture of Medicinal Gases

EMA and PIC/S have published a concept paper announcing a targeted revision of Annex 6 Manufacture of Medicinal Gases of the EU GMP Guide. The last update dates from 2010. The revision aims to reflect current manufacturing practice, technological progress and lessons learned from the COVID-19 pandemic.

Read more
EMA: Concept Paper on the Revision of Annex 15

EMA: Concept Paper on the Revision of Annex 15

EMA and PIC/S have published a concept paper outlining a targeted revision of Annex 15 (Qualification and Validation).

Read more
What do Typical Manufacturing Processes for Sterile Products look like?

What do Typical Manufacturing Processes for Sterile Products look like?

Here's the answer:
Read more
Human Resource Management as a Key to Success

Human Resource Management as a Key to Success

The pharmaceutical industry in Germany and other countries, too, faces considerable challenges in the area of human resource management. These problems have far-reaching implications for the competitiveness and innovative power of the industry.

Read more
EMA: Reflection Paper on the Qualification of Non-Mutagenic Impurities (NMIs)

EMA: Reflection Paper on the Qualification of Non-Mutagenic Impurities (NMIs)

The EMA has published a new reflection paper outlining its current thinking on the qualification of non-mutagenic impurities (NMIs). The paper addresses recommended approaches for evaluating the safety of new or increased impurity levels, particularly when such impurities exceed the ICH Q3A/Q3B qualification thresholds and are identified after completion of non-clinical toxicology studies.

Read more
EMA: Discussions on the Revised ERA Guideline

EMA: Discussions on the Revised ERA Guideline

During the second industry stakeholder webinar on the revised guideline on environmental risk assessment (ERA) for medicinal products for human use, the European Medicines Agency (EMA) addressed key implementation challenges observed during the first year of application.
Read more
Previous
Next